Akero Therapeutics, Inc. Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKRO

Classificação em ações #3678
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Preço da ação
$54.65
Última sincronização: 2025-12-09
Valor de mercado
$4.50B
Variação (1 dia)
0.00%
Variação (1 ano)
1.94%
País
US
Negociar Akero Therapeutics, Inc. (AKRO)

Categoria

Healthcare
Histórico de preços das ações de Akero Therapeutics, Inc. (AKRO)
Preço de fecho mais alto: $54.59 em 2025-12-01

Preço de fecho mais baixo: $18.95 em 2019-06-01
Histórico de preços das ações da Akero Therapeutics, Inc. de 2019 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -0.66%
2025 84.69%
2024 39.17%
2023 -53.49%
2022 118.99%
2021 -23.63%
2020 26.67%
2019 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$758.21 7.77%
CH